- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 87,540 | 19.06.24 14:12:54 | -0,990 | -1,12% | 87,520 | 87,570 | 87,890 | 88,530 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 963,800 | 19.06.24 14:34:57 | -5,800 | -0,60% | 963,600 | 969,600 | 964,400 | 969,600 |
